Sources Directory     A to Z Index     Topic Index News Releases     RSS Sources Select News RSS Feed     Sources Calendar      

Alzheimer Disease/Research: Experts and Sources
Sources Directory - Subject Index


Sources Experts & Spokespersons

The Cochrane Collaboration/The Cochrane Library
The Cochrane Collaboration is an international not-for-profit and independent organization dedicated to making up-to-date, accurate information about the effects of health care readily available worldwide. It produces and dissemin...

News Releases

Alzheimer’s Weekly names ANAVEX 2-73 the number one most promising trial drug in Alzheimer’s disease and Anavex’s Phase I clinical program as “Trial o
2011-01-11
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
ANAVEX 2-73 has been named 2010’s “most promising trial drug” by the editorial staff at Alzheimer’s Weekly.
ANAVEX 2-73 advances Phase I clinical trial for Alzheimer’s disease
2011-05-26
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide an update on its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead candidate for Alzheimer’s disease....
Anavex adds Dr. Paul Aisen to Scientific Advisory Board
2011-02-16
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. (OTCBB: AVXL) has announced the appointment of Dr. Paul Aisen to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the company to support ...
Anavex advances second lead compound; initiates scale-up manufacturing of ANAVEX 1-41
2011-06-08
Anavex Life Sciences Corp.
Anavex Life Sciences Corp., (“Anavex”) (OTCBB: AVXL) today announced the initiation of scale-up manufacturing of ANAVEX 1-41, its lead compound for a range of important neurological diseases and a pot...
Anavex appoints contract research organizations to initiate Phase I/IIa clinical programs, regulatory strategies in Alzheimer's disease
2010-08-10
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp signs a definitive master services agreement with Genesis BioPharma Group and ABX-CRO Advanced Pharmaceutical Services to begin clinical studies and regulatory filings for it...
Anavex appoints Dr. Jeffrey Cummings to its Scientific Advisory Board
2011-03-01
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. has announced the appointment of Dr. Jeffrey Cummings to the Scientific Advisory Board as a clinical expert. The Scientific Advisory Board works closely with the company to ...
Anavex appoints Dr. Rachelle Doody to Scientific Advisory Board
2011-02-23
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced the appointment of Dr. Rachelle Doody to the Scientific Advisory Board (SAB) as a clinical expert. The SAB works closely with the comp...
Anavex comments on new Alzheimer’s disease diagnostic guidelines
2011-05-17
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today commented on new diagnostic criteria and guidelines for Alzheimer’s disease published recently by the National Institute on Aging (NIA) and th...
Anavex comments on President Obama’s signing of National Alzheimer’s Project Act into law
2011-01-18
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) today commented on President Obama’s signing of the National Alzheimer’s Project Act (NAPA) into law. The passage of this landmark legislation lays ...
Anavex files Phase I regulatory submission for ANAVEX 2-73 in Alzheimer’s disease
2011-01-11
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. has filed regulatory submission for ANAVEX 2-73 with the German Health Authority, BfArM, and the local Ethics Committee of Saxony to begin clinical studies for ANAVEX 2-73, ...
Anavex presents data on neuroprotective evidence for ANAVEX 2-73, lead compound for Alzheimer’s disease
2011-07-26
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of its second poster presentation at the Alzheimer’s Association International Conference (AAIC) held in Paris, enti...
Anavex presents data on potential dual utility of ANAVEX 2-73 in both amyloid and tau pathology
2011-07-25
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to provide a summary of the first of two poster presentations at the Alzheimer’s Association International Conference (AAIC) held in Pari...
Anavex raises $1.575 million
2011-07-11
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that it has raised US$1,575,000.00 through the exercise of warrants. Funds will be used to continue the Phase I clinical tria...
Anavex rapidly advances ANAVEX 2-73 for Alzheimer’s disease, Phase I clinical trial progressing well
2011-07-06
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) has commenced the 30 mg dose step in its ongoing Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead drug candidate for Alzheimer’s d...
Anavex Receives Approval to Commence Phase I Clinical Trial in Alzheimer’s Disease
2011-03-21
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced that its clinical trial application (CTA) for ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease, has been approved by t...
Anavex Screening Healthy Volunteers For Phase I, First-In-Human Clinical Study in Alzheimer’s Disease
2011-03-31
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) has announced screening of the first healthy volunteers for the Phase I clinical study of ANAVEX 2-73, its lead compound for the treatment of Alzhei...
Anavex strengthens management team with addition of VP, Clinical Development & Medical Affairs
2011-02-16
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) announced the addition of Dr. Angelos Stergiou to the executive management team in the role of Vice President, Clinical Development & Medical Affair...
Anavex to present at Alzheimer’s Association International Conference on Alzheimer’s Disease
2011-07-15
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. (“Anavex”) (OTCBB: AVXL) today announced that new data on ANAVEX 2-73, the company’s lead compound for Alzheimer’s disease (AD) currently in Phase I clinical trials, will be...
Anavex to present at Rodman & Renshaw Healthcare Conference September 13 in New York
2010-09-08
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. ("ANAVEX") (OTCBB: AVXL) is pleased to announce that Dr. Cameron Durrant, the company#s Executive Chairman, will be presenting at the Rodman & Renshaw 12th Annual Healthcare...
Anavex: First-In-Human Dosing Commenced in ANAVEX 2-73 Clinical Trial for Alzheimer’s Disease
2011-04-20
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Anavex Life Sciences Corp. (OTCBB: AVXL) today announced that the first healthy human volunteers have been initially dosed in its Phase I clinical trial to evaluate ANAVEX 2-73, the company’s lead com...
Sources welcomes Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert
2010-07-23
Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biot
Sources welcomes a new member: Dr. Cameron Durrant, MD, MBA, Alzheimer's Disease and Pharmaceuticals/Biotech Expert.

Sources Bookshelf

Musicophilia
Tales of Music and the Brain
Sacks, Oliver
Book
2007
Oliver Sacks explores the place music occupies in the brain and how it affects the human condition. In Musicophilia, he examines the power of music through the individaul experiences of patients, musi...


Sources is an online portal and directory for journalists, writers, news editors, researchers. Use Sources to find experts, media contacts, spokespersons, scientists, lobbyists, officials, speakers, university professors, researchers, newsmakers, CEOs, executive directors, media relations contacts, spokespeople, talk show guests, PR representatives, Canadian sources, story ideas, research studies, databases, universities, colleges, associations, businesses, government, research institutions, lobby groups, non-government organizations (NGOs), in Canada and internationally.
© Sources 1977-2016. The information provided is copyright and may not be reproduced in any form or by any means (whether electronic, mechanical or photographic), or stored in an electronic retrieval system, without written permission of the publisher. The content may not be resold, republished, or redistributed. Indexing and search applications by Ulli Diemer and Chris DeFreitas.